Liposomal cyclosporin pharmaceutical formulation

Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Liposomes

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 9127

Patent

active

056837143

ABSTRACT:
An improved liposomal cyclosporin therapeutic formulation, comprising phosphatidylcholine, phosphatidylglycerol and a cyclosporin in a mole ratio of from 25:3:1 to 17:3:1 is described. The formulation includes unilamellar vesicles having reduced toxicity. The formulation is used as an immunosuppressive agent and is an enhancer of the efficacy of antineoplasties for drug resistant cancer cells. A method is also provided for inhibiting the growth of cancer cells.

REFERENCES:
patent: 4608211 (1986-08-01), Handjani et al.
patent: 4663167 (1987-05-01), Berestein
patent: 4692433 (1987-09-01), Hostetler
patent: 4797285 (1989-01-01), Barenholz et al.
patent: 4812312 (1989-03-01), Lopez-Berestein et al.
patent: 4895719 (1990-01-01), Radhakrishan et al.
patent: 4913902 (1990-04-01), Kilpatrick et al.
patent: 4952405 (1990-08-01), Young
patent: 4963362 (1990-10-01), Rahman
patent: 5000887 (1991-03-01), Tenzel et al.
patent: 5023087 (1991-06-01), Young
Szoka Ann. Rev. Biophys. Bioeng. 1980. 9, p. 467.
Venkataan. J. Pharm. Sciences 79, #3, Mar. 1990.
Deamer. Liposome Prep. Chap I, 1983 p. 27.
Gilbert et al., Characterization and Administration of Cyclosporin Liposomes as a Small-Particle Aerosol, Chemical Abstracts, vol. 120, No. 14, 4 Apr. 1994, Columbus, Ohio, US, Abstract No. 173337q.
Van de Vrie, W., "In vitro and in vivo chemosensitizing effect of cyclosproin A on an intrinsic multidruresistant rat colon tumour", Cancer Research Clinical Oncology vol. 119, pp. 609-614 (1993).
Freise, Chris E., "The Increased efficacy and decreased nephrotoxicity of a cyclosporine liposome", Transplantation vol. 57, No. 6, pp. 928-932 (Mar. 1994).
Sonneveld, P, "Clinical modulation of multidrug resistance in multiple myeloma: Effect of cyclosporin on resistant tumor cells", Journal of Clinical Oncology vol. 12, No. 8, pp. 1584-1591 (Aug. 1994).
Colombo, Tina, "Cyclosporin a markedly changes the distribution of doxorubicin in mice and rats", The Journal of Pharmacology and Experimental therapeutics, vol. 269, No. 1, pp. 22-27 (1994).
Yano, Seiji, "Cyclosporin a enhances susceptibility of multi-drug resistant human cancer cells to anti P-glycoprotein antibody-dependent cytotxicity of monocytes, but not of lymphocytes", J. Cancer Re vol. 85, pp. 194-203 (Feb. 1994).
van der Graaf, Winette T.A., "Effects of amiodarone, cyclosporin A, and PSC 833 on the cytotoxicity of mitoxantrone, doxorubicin and vincristine in non-P-glycoprotein human small cell lung cancer cell lines", Cancer Research vol. 54, pp. 5368-5373 (Oct. 15, 1994).
Erlichman, Charles, "Phase I pharmacokinetic study of cyclosporin a combined with doxorubicin", Cancer Research vol. 53, pp. 4837-4842 (Oct. 15, 1983).
Sonneveld, Pieter, "Modulation of multidrug-resistant multiple myeloma by cyclosporin", The Lance vol. 340, No. 8814, pp. 255-259 (Aug. 1, 1992).
Samuels, Brian L., "Modulation of vinblastine resistance with cyclosporine: A phase I study", Clinic Pharmacology & Therapeutics vol. 54, No. 4, pp. 421-429 (Oct. 1993).
Sikic, Branimir I., "Modulation of multidrug-resistance: At the Threshold", Journal of clinical Onocolog vol. 11, No. 9, pp. 1629-1635 (Sep. 1993).
Thierry, Alain R., "Effect of liposomes on P-glycoprotein function in multidrug-resistant cells", Biochemical and Biophysical Research Communications vol. 187, No. 2, pp. 1098-1105 (Sep. 16 1992).
Rahman, Aquilur, "Liposome-mediated modulation of multidrug resistance in human HL-60 leukemia cells", Journal of the National Cancer Institute vol. 84, No. 24, pp. 1909-1915 (Dec. 16, 1992).
Dalton, William S., "Drug resistance modulation in the laboratory and the clinic", Seminars in Oncology vol. 20, No. 1, pp. 64-69 (Feb. 1993).
Clynes, Martin, "Cellular models for multiple drug resistance in cancer", In Vitro Cell. Dev. Biol. 29A, pp. 171-179 (Mar. 1993).
Dietel, Manfred, "Second International symposium on cytostatic drug resistance", Cancer Research vol. 53, pp. 2683-2688 (Jun. 1, 1993).
Twentyman, Peter R., "A possible role for cyclosporins in cancer chemotherapy", Anticancer Researc vol. 8, pp. 985-994 (1988).
List, Alan F., "Phase I/II trial of cycloporine as a chemotherapy resistance modifier in acute leukemia", Journal of Clinical Oncology vol. 11, No. 9, pp. 1652-1660 (Sep. 1993).
Boesch, Danielle,"In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833", Cancer Research vol. 51, pp. 4226-4233 (Aug. 15, 1991).
Yahanda, Anne M., "Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance", Journal of Clinical Onocology vol. 10, No. 10, pp. 1624-1634 (Oct. 1992).
Benedicte Jachez, Rene, "Restoration of taxol sensitivity of multidrug resistant cells by the cyclosporine SDZ PSC 833 and the cyclopeptolide SDZ 280-446", Journal of the National cancer Institute vol. 85, No. 6, pp. 478-483 (Mar. 17, 1993).
Slater, Lewis M., "Cyclosporin a reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro", Cyclosporin A Corrects Vincristine and Daunorubicin Resistance vol 77, pp. 1405-1408 (Apr. 1986).
Friche, Ellen, "Comparison of cyclosporin A and SDZ PSC 833 as multidrug resistance modulators i a daunorubicin resistant Ehrlich ascites tumor", Cancer Chemotherapy and Pharmacology vol. 30, pp. 235-237 (1992).
Shoji, Y, "Verapamil and cyclosporin A modulate doxorubicin toxicity by distinct mechanisms", Cancer Letters vol. 57, pp. 209-218 (1991).
Hu, Xiu F., "Combined use of cyclosporin A and verapamil in modulating multidrug resistance in human leukemia cell lines", Cancer Research vol. 50, pp. 2953-2957 (May 15, 1990).
Meador, Josephine,"Enhancement by cyclosporin A of daunorubicin efficacy in Ehrillich ascites carcinoma and murine hepatoma 129", Cancer Research vol. 47, pp. 6216-6219 (Dec. 1, 1987).
Kuhl, Jorn-Sven, "Use of etoposide in combination with cyclosporine for purging multidrug resistant leukemic cells from bone marrow in a mouse model". Advances in Bone Marrow Purgin and Processing, pp. 25-34 (1992).
Nygren, P."Verapamil and cyclosporin a sensitize human kidney tumor cells to vincristine in absence of membrane P-glycoprotein and without apparent changes in the cytoplasmic free Ca.sup.2+ concentration", Bioscience Reports vol. 10, No. 2, pp. 231-237, (1990).
Twentyman, P.R., "Chemosensitisantion by verapamil nd cyclosporin A in mouse tumour cells expressing different levels of P-glycoprotein and CP22 (Sorcin)", Cancer vol. 62, pp. 89-95 (1990).
Saeki, Tohru, "Human P-glycoprotein transports cycloporin A and FK506", the Journal of Biological Chemistry vol. 268, No. 9, pp. 6077-6080 (Mar. 25, 1993).
Hsieh et al. "Preliminary Report: The Use of Liposome-Encapsulated Cyclosporine In a Rat Model", Transplantation Proceedings, vol. XVII, Feb. 1985, 1397-1400.
Stuhne-Sekalec et al. "Encapsulation fo Cyclosporine by Phosphatidylinositol-Cholesterol Liposomes", Transplantation 41, 659-660, 1986.
Stuhne-Sekalec et al. "Co-encapsulation of Cyclosporin and Insulin by Lipo-somes", J. Biochem. Biophys. Methods 13, 23-27, 1986.
Gruber et al. "Liposomal Formulation Eliminates Acute Toxicity and Pump Incompatibility of Parenteral Cyclosporine", Pharm. Res. 6, 601-607, 1989.
Stuhne-Sekalec et al. "Liposomes as Cyclosporin A Carriers: Positively Charged . . . Phosphatidylinositol", J.Microencapsulation 6, 177-182, 1989.
Venkatarum et al. "Pharmacokinetics of Two Alternative Dosage Forms Cyclosporine: Liposomes and Intralipid" J. Pharm. Sci. 79, 216-219, 1990.
Stuhne-Sekalec et al. "Liposomes as Cyclosporin A Carriers: The Influence . . . Cyclosporin A", J. Microencapsulation 8, 283-294, 1991.
Stuhne-Sekalec et al. "Liposomes as Carriers of Cyclosporin A", J. Microen-capsulation 8, 441-446, 1991.
Stuhne-Sekalec et al. "Liposomes as Cyclosporin A Carriers: ESR Study . . . Phosphatidylglycerol Liposomes", J. Microencapsulation 8, 455-463, 1991.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Liposomal cyclosporin pharmaceutical formulation does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Liposomal cyclosporin pharmaceutical formulation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Liposomal cyclosporin pharmaceutical formulation will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-1831147

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.